<DOC>
	<DOCNO>NCT02205099</DOCNO>
	<brief_summary>This single-site , randomize , double-blind , placebo-controlled , multiple dose , flexible dosage range , PK PD study SKL15508 monotherapy subject stable schizophrenia .</brief_summary>
	<brief_title>A Safety , Tolerability , PK PD Study Multiple Oral Doses SKL15508 Subjects With Stable Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . The subject , applicable , subject 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 2 . Participants nonsterile sexually active agree use doublebarrier method contraception ( must use regardless contraception use ) time provide informed consent throughout duration study 12 week last dose study drug . Nonsterile male must advise donate sperm woman donate ovum throughout duration study 12 week last dose study drug . 3 . Must male nonpregnant , nonlactating female subject , 18 60 year age , inclusive 4 . Has body mass index ( BMI ) 18.0 38.0 kg/m2 , inclusive 5 . Has clinical diagnosis schizophrenia , opinion Investigator , able safely prescribe antipsychotic medication participate study high likelihood deteriorate 3week timeframe standard care outpatient Screening Period 6 . Has receive stable dose antipsychotic medication least 1 month Screening 7 . Has acute exacerbation psychosis hospitalization treatment schizophrenia least 3 month Screening 8 . By history , mark change smoking tobacco/nicotine use 30 day Screening . 9 . Must reside stable residence least 8 week Screening Visit 1 . At risk suicide ( e.g. , per Columbia Suicide Severity Rating Scale [ CSSRS ] ) make suicide attempt 6 month Screening 2 . Has know sensitivity sulfurcontaining drug sulfate food 3 . Taking medication know influence coagulation , acetylsalicylic acid ( aspirin ) , include prescription , herbal remedy , vitamin supplement overthecounter product 4 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal endocrine disease abnormality ( disease study ) , may impact ability subject participate potentially confound study result 5 . Has positive urine drug result drug abuse ( i.e. , illicit , illegal without valid prescription medical need ) Screening Admission 6 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 45 day Day 1 7 . Has abnormal ( clinically significant ) electrocardiogram ( ECG ) Screening unit admission day 8 . Has blood pressure pulse rate outside protocol define range 9 . Has QT interval PR outside protocol define range 10 . Has abnormal laboratory value suggest clinically significant underlying disease 11 . Has history primary DSMIV axis I diagnosis schizophrenia 12 . Has medical condition schizophrenia ( e.g. , dementia , antisocial personality , borderline personality disorder ) cause cognitive impairment interfere performance completion studydefined procedure 13 . Has take medication medical condition le 2 month even stable dose regimen 14 . Currently take lithium psychotropic medication discontinue safety reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>